Informing the development of β-lactam—β-lactamase inhibitor combinations through a comparison of in vitro data
Abstract
Mortality rates associated with antimicrobial resistance are increasing at an alarming rate and are becoming one of the most serious threats to global health. Paradoxically, investment in the development of new antibacterial agents is limited as a result of multiple factors, including resistance, which have the potential to shorten the clinical lifespan of an antibacterial agent. Improvements in the tools used to predict the success or failure of drug candidates have been shown to reduce the overall cost of the drug discovery process. β-Lactamases are drug-modifying enzymes that can hydrolyse and inactivate the β-lactam antibiotics. The development of β-lactamase inhibitors (BLIs) can enable the re-sensitisation of bacteria previously resistant to the β-lactams (BLs). There are nine β-lactam/β-lactamase inhibitor (BL/BLI) combinations available for use in clinical practice. This review presents a summary of the in vitro performance of the nine currently marketed BL/BLI combinations in synergy assays, serving as a comparative reference for researchers developing new combinations.
Related
- Culture Dimensionality Shapes Drug Sensitivity to Kinase Inhibitor Combinations with Epigenetic or Metabolic Inhibition in a Hepatocellular Carcinoma Model
- In Vitro and In Vivo Efficacy of the Broad-Spectrum β-Lactamase Inhibitor APC24-7 in Combination with Meropenem Against Carbapenem-Resistant Enterobacterales.
- Immune Checkpoint Inhibitor-Related Hepatitis Versus Classical Autoimmune Hepatitis: A Retrospective Multidomain Phenotype Comparison
- Comparison of Survival Outcomes with First-Line PARP Inhibitor Maintenance According to BRCA Mutation and Homologous Recombination Deficiency Status in Advanced Ovarian Cancer: A Single-Center Retrospective Cohort Study
- Serabelisib, a Selective PI3Kα Inhibitor, for Slow-Flow Vascular Malformations in a Phase 3 Multicenter Single-Arm Study with Natural History Comparison
BibTeX
@article{mansour2026informing,
title = {{Informing the development of β-lactam—β-lactamase inhibitor combinations through a comparison of in vitro data}},
author = {Elissar Mansour and Jonathan J. Du and Mohamed Fares and David E. Hibbs and Paul W. Groundwater},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1998984},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1998984},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Informing the development of β-lactam—β-lactamase inhibitor combinations through a comparison of in vitro data
AU - Elissar Mansour
AU - Jonathan J. Du
AU - Mohamed Fares
AU - David E. Hibbs
AU - Paul W. Groundwater
PY - 2026
DA - 2026/11/05
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1998984
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1998984
AB - Mortality rates associated with antimicrobial resistance are increasing at an alarming rate and are becoming one of the most serious threats to global health. Paradoxically, investment in the development of new antibacterial agents is limited as a result of multiple factors, including resistance, which have the potential to shorten the clinical lifespan of an antibacterial agent. Improvements in the tools used to predict the success or failure of drug candidates have been shown to reduce the overall cost of the drug discovery process. β-Lactamases are drug-modifying enzymes that can hydrolyse and inactivate the β-lactam antibiotics. The development of β-lactamase inhibitors (BLIs) can enable the re-sensitisation of bacteria previously resistant to the β-lactams (BLs). There are nine β-lactam/β-lactamase inhibitor (BL/BLI) combinations available for use in clinical practice. This review presents a summary of the in vitro performance of the nine currently marketed BL/BLI combinations in synergy assays, serving as a comparative reference for researchers developing new combinations.
SN - 1663-9812
ER -